Lunaphore closes a CHF 5.3M Series B financing round
Our portfolio company Lunaphore has successfully closed their CHF 5.3 M Series B financing round setting itself on the right track to achieve quick market entry.
Lunaphore Technologies SA is a Swiss medtech firm developing innovative next-generation devices for cancer tissue diagnostics.
The closing of the oversubscribed round was finalized in August 2018. In addition to existing investors, new funds participating in this round include Occident Group, Zürcher Kantonalbank, as well as investment funds from Asia, Switzerland and United Kingdom. The investment will enable CE marking of Lunaphore’s products and support product launch.
Lunaphore’s CEO, Ata Tuna Ciftlik, said: “Following the announcement of partnerships in the last months, Lunaphore’s standing as a key and enabling technology in the tissue diagnostic market has been validated one more time with this oversubscribed financing round. Our management team is thrilled by the investors’ confidence and interest”.